Tuberculosis, extrapulmonary Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Tuberculosis, extrapulmonary. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Tuberculosis, extrapulmonary receives a directional strategic score of 64/100, combining unmet need (78/100), competitive intensity (79/100, where higher means more competition) and market attractiveness (78/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

MYCOBACTERIUM infections of organs other than the lung.

The reproducible entity is Patsnap disease ID 754fa682ba97464c8ce926b3c411c54d with MeSH identifier D000092225. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Annual epidemiological report Reporting on 2011 surveillance data and 2012 epidemic intelligence data 2013 Severe acute respiratory syndrome (SARS)

Of 72 334 cases reported in 2011, 55 939 (77.3%) suffered from pulmonary TB, including 4 586 (6.3%) with addi- tional extrapulmonary manifestations. Purely extrapul- monary TB affected 16 116 (22.3%), and for 279 (0.4%) of all reported cases, site was not reported. Country- specific proportions of extrapulmonary TB in 2011 ranged from 3.9% in Hungary to 66.7% in Iceland. The overall reported rate had been stable at 3.2 to 3.5 per 100 000 since 2002. Of 16 116 purely extrapulmonary TB cases notified in 2011, 3 521 (21.8%) had lymphatic TB, 3 084 (19.1%) had pleural TB, and 3 320 (20.6%) suffered from TB at other extrapulmonary sites. No site was specified for 6 191 (38.4%) extrapulmonary TB cases. In children under 15 years of age, extrapulmonary TB accounted for 1 347 (42.8%) of 3 145 cases with site infor- mation, and in adults 15 years of age and older for 14 761 (21.4%) of 68 851 cases. Origin of TB cases In 2011, 51 191 (72.2%) of 72 334 reported TB cases were born in an EU/EEA Member State or had citizenship in an EU/EEA Member State, 18 646 (25.8%) were of for- eign originii, and 1 497 (1.8%) of unknown origin. Of all foreign TB cases, 6 226 (33.4%) were from Asia (outside the WHO European Region), 5 767 (30.9%) from Africa, 1 880 (10.1%) from other EU/EEA countries, 1 596 (8.4%) ii The geographic origin of a TB case is classified according to place of birth (born in the country/foreign-born, reported by 24 countries) or, if unavailable, citizenship (citizen/non-citizen, five countries).

Review the epidemiology source

Epidemiology evidence 2: A Questionnaire Survey on Extrapulmonary Tuberculosis Control and Prevention — China, 2021 A Questionnaire Survey on Extrapulmonary TuberculosisControl and Prevention — China, 2021

World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. https://www.who.int/publications/i/ item/9789240037021. 1. Cukic V, Ustamujic A. Extrapulmonary tuberculosis in federation of Bosnia and Herzegovina. Mater Sociomed 2018;30(2):153 − 6. http://dx. doi.org/10.5455/msm.2018.30.153-156. 2. Yao S, Fang XH. Interpretation and consideration of 2020 Edition Technical Specifications for TB Prevention and Control in China. J Trop Dis Parasitol 2020;18(3):138 − 41,137. http://dx.doi.org.sutd.idm.oclc.org/10.3969/ j.issn.1672-2302.2020.03.002. (In Chinese). 3. Zhao YL, Liu JJ. Facing the challenge of tuberculosis: towards "End TB in China by 2035". China CDC Wkly 2021;3(12):243 − 6. http://dx. doi.org/10.46234/ccdcw2021.070. 4. Li T, Du X, Liu XQ, Li YH, Zhao YL. Implementation performance of tuberculosis control in China: 2011-2020. China CDC Wkly 2021;3(12):252 − 5. http://dx.doi.org.sutd.idm.oclc.org/10.46234/ccdcw2021.073. 5. National Health Commission. Stop TB action plan (2019-2022). http:// www.nhc.gov.cn/jkj/s3589/201906/b30ae2842c5e4c9ea2f9d5557 ad4b95f.shtml. [2019-6-13]. (In Chinese). 6. Liu Y, Xu CH, Wang ZY, Wang XM, Wang YH, Zhang H, et al. A cross-sectional study on economic burden of pulmonary tuberculosis cases from designated tuberculosis hospital. Chin J Epidemiol 2019;40(5):559 − 64. http://dx.doi.org.sutd.idm.oclc.org/10.3760/cma.j.issn.0254-6450. 2019.05.013. (In Chinese). 7. Banta JE, Ani C, Bvute KM, Lloren JIC, Darnell TA. Pulmonary vs. extra-pulmonary tuberculosis hospitalizations in the US [1998–2014]. J Infect Public Health 2020;1(13):131 − 9. http://dx.doi.org.sutd.idm.oclc.org/

Review the epidemiology source

Epidemiology evidence 3: Annual epidemiological report Reporting on 2010 surveillance data and 2011 epidemic intelligence data Avian influenza and other animal influenzas

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It typically affects the lungs (pulmonary TB), but can affect other sites as well (extrapulmonary TB). The disease is spread through droplet transmission when people who are sick with pulmonary TB expel bacteria, for example by cough­ ing. In general, a relatively small proportion of people infected with Mycobacterium tuberculosis will go on to develop TB disease; however, the probability of devel­ oping TB is much higher among people with impaired immunity, such as in untreated HIV infection. Epidemiological situation in 2010 In 2010, 73 996 TB cases (possible, probable and con­ firmedi) were reported by 27 European Union countries, Iceland and Norway (Table 2.1.3), showing a decrease of 5 685 cases compared with 2009. Over 76% of cases occurred in the seven countries reporting 3 000 cases or more each (France, Germany, Italy, Poland, Romania, Spain and the United Kingdom). The overall TB rate in 2010 was 14.6 per 100000 popula­ tion. Rates higher than 20 per 100 000 were reported by Romania (98.2), Lithuania (58.2), Latvia (41.5), Bulgaria (35.0), Portugal (24.7) and Estonia (24.5). The overall rate was 7.1% lower than 2009, reflecting a net decrease in 22 countries when compared with 2009. The overall average annual decrease between 2006 and 2010 was 4.4%. Age and gender distribution Among the new TB cases and relapses reported in 2010, 80% more males than females (male/female ratio: 1.8) were affected. This gender imbalance was largely restricted to those aged 25 years and old

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Tuberculosis, extrapulmonary, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Tuberculosis, extrapulmonary thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: ALK5

Transmembrane serine/threonine kinase forming with the TGF-beta type II serine/threonine kinase receptor, TGFBR2, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis (PubMed:33914044). The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. For instance, TGFBR1 induces TRAF6 autoubiquitination which in turn results in MAP3K7 ubiquitination and activation to trigger apoptosis. Also regulates epithelial to mesenchymal transition through a SMAD-independent signaling pathway through PARD6A phosphorylation and activation.

The mechanism anchor is TGFBR1. It is a pathway hypothesis, not a claim that every Tuberculosis, extrapulmonary patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 83 registered studies. Recent sampled records include:

• NCT07778082 — MBLA to Differentiate IRIS From Treatment Failure in Extrapulmonary Tuberculosis (MBLA_IRIS); Not yet recruiting; Not Applicable; sponsor Research Center Borstel; enrollment 100.
• CTR20262088 — 富马酸贝达喹啉片（规格：100mg）生物等效性试验; 进行中 （尚未招募）; Not Applicable; sponsor Liye Pharmaceutical Co. Ltd.; enrollment Target enrollment: 国内: 40  Enrolled: 国内: 登记人暂未填写该信息 Actual enrollment: 国内: 登记人暂未填写该信息.
• CTR20250317 — 评价结核菌素纯蛋白衍生物（TB-PPD）在6岁及以上人群中进行结核病感染的诊断能力，并评估其安全性的临床III期试验; 进行中 （尚未招募）; Phase 3; sponsor Chengdu Keen Biological Technology Co., Ltd.; enrollment Target enrollment: 国内: 1220  Enrolled: 国内: 登记人暂未填写该信息 Actual enrollment: 国内: 登记人暂未填写该信息.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate TGFBR1 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Tuberculosis, extrapulmonary merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if TGFBR1 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Tuberculosis, extrapulmonary is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.